Retension Pharmaceuticals has announced the appointments of Alison D. Schecter, M.D., as Chief Medical Officer and Alex Schwartz as Chief Financial Officer. These seasoned executives bring extensive clinical development and financial expertise to the company as it advances RTN-001 through its Phase 2b clinical trial.
Who to call at Retension Pharmaceuticals, and when
A new leader at Retension Pharmaceuticals brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Retension Pharmaceuticals raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Retension Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Retension Pharmaceuticals. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Retension Pharmaceuticals
Location
Mclean, Virginia, United States
About
Retension Pharmaceuticals is developing RTN-001, a differentiated, tissue-targeted PDE5 inhibitor that has been optimized for the treatment of uncontrolled hypertension. RTN-001 has been evaluated in over 265 subjects across 9 clinical trials. In these studies, RTN-001 was well tolerated and demonstrated a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension. RTN-001 is a second generation PDE5i that preferentially distributes to cardiovascular tissues, where it acts to mediate a sustained and clinically significant impact on central and brachial blood pressure in patients with uncontrolled hypertension.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Retension Pharmaceuticals changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
McleanBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharma